Research programme : antibody-drug conjugates - Angiex
Latest Information Update: 22 Apr 2024
At a glance
- Originator Angiex
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Apr 2024 Early research in Cancer in USA (Parenteral) (Angiex pipeline, April 2024)
- 28 Apr 2022 Angiex has patents pending entitled "Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same" worldwide
- 29 Aug 2017 Angiex signs a collaboration agreement with Merck to accelerate clinical development of antibody-drug conjugate in treatment of Cancer